CYDY (CytoDyn) EBIT per Share: $-0.03 (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYDY CytoDyn Inc CYDY
27 GF Score
Price $0.21
! 1 Warning Sign
View Full Analysis

What is CytoDyn EBIT per Share?

CytoDyn CYDY -2.09% 27 EBIT per Share is $-0.03 as of Feb. 2026. GuruFocus rates CYDY with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,173 Biotechnology companies, CytoDyn ranks worse than 85251.41% on this metric.

CytoDyn's EBIT per Share for the three months ended in Feb. 2026 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was $-0.03.

During the past 12 months, the average EBIT per Share Growth Rate of CytoDyn was -383.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CytoDyn's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CytoDyn was 50.00% per year. The lowest was -60.70% per year. And the median was 3.15% per year.

CYDY's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

CytoDyn's EBIT for the three months ended in Feb. 2026 was $-4.08 Mil.

CytoDyn  (OTCPK:CYDY) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CytoDyn EBIT per Share Related Terms

CytoDyn EBIT per Share Historical Data

* Premium members only.

The historical data trend for CytoDyn's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn EBIT per Share Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.20 -0.29 -0.09 -0.05 0.01

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.02 -0.00
CYDY
27GF Score
CytoDyn Inc CYDY
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CytoDyn's EBIT per Share for the fiscal year that ended in May. 2025 is calculated as

EBIT per Share(A: May. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=8.576/1242.922
=0.01

CytoDyn's EBIT per Share for the quarter that ended in Feb. 2026 is calculated as

EBIT per Share(Q: Feb. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.076/1275.184
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.03 mean?
CytoDyn (CYDY) has a EBIT per Share of $-0.03 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CytoDyn and its competitors. According to the industry distribution chart, CytoDyn ranks #999999 out of 1173 companies in the Biotechnology industry.
Is CytoDyn's EBIT per Share too high?
CytoDyn's current EBIT per Share is $-0.03. Based on the distribution chart, CytoDyn ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoDyn has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's EBIT per Share compare to VSTM and IRD?
According to the Biotechnology industry distribution chart, CytoDyn ranks #999999 out of 1173 companies for EBIT per Share. This places CytoDyn in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CytoDyn and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoDyn's current EBIT per Share is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (CYDY) has a current EBIT per Share of $-0.03. The current EBIT per Share is $-0.03. CytoDyn's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CytoDyn (CYDY), the current EBIT per Share is $-0.03 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges 296:Germany
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
27GF Score

Get the complete analysis for CYDY

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price